CMC Biologics expands GMP manufacturing capacity in Denmark

By Melissa Fassbender

- Last updated on GMT

The expansion in Denmark is part of the company's ongoing global manufacturing capacity expansion. (Image: iStock/titoOnz)
The expansion in Denmark is part of the company's ongoing global manufacturing capacity expansion. (Image: iStock/titoOnz)

Related tags Europe European union

CMC Biologics as upped its production capacity at its Copenhagen facility with plans to have equivalent capacity on both sides of the Atlantic in 2017.

The company announced today that it has completed the first stage of the expansion for its Copenhagen, Denmark- based manufacturing facility with the addition of a single-use Bioreactor 3PACK facility, currently ready for production runs.

The 3PACK contains three 2,000L single-use production bioreactors and associated seed train for scale up. According to the company, the facility allows for flexible production with scales from 2,000L to 6,000L in a single production suite. Additionally, the bioreactors can be run singly, simultaneously, sequentially, or in staggered mode.

"With this additional cGMP production capacity, we are continuing our long-term strategy to provide innovative solutions to our customers, from early-stage development to large-scale commercial production​," said Patricio Massera, General Manager at the Copenhagen Site.

The company plans to add three additional 2,000L single-use production bioreactors in 2017 to establish a Bioreactor 6PACK line identical to the services in its US and European manufacturing facilities.

"Establishing this unique facility design in both our US and European manufacturing facilities enables us to significantly optimize process transfer and synergies between the sites​," said Gustavo Mahler, PhD, President and CEO of CMC Biologics. "We are changing the way CMOs operate and we continue to generate innovative solutions for our clients​."

As Outsourcing-Pharma.com previously reported​, the company received regulatory approval for the upgrades in October 2013. The facility is approved for GMP production by the EMA and is also fully US Food and Drug Administration (FDA) compliant. 

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Webinars

Headlines